Print

Catalyst Pharmaceutical Partners, Inc. Announces Delay to CPP-109 Top-Line Results  
9/26/2012 6:51:44 AM

CORAL GABLES, FL, September 26, 2012 -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it has been advised by the Department of Veterans Affairs Cooperative Studies Program (VACSP) that the availability of top-line results from Catalyst's CPP-109 (vigabatrin) Phase II(b) trial for cocaine addiction will be delayed. VACSP now expects to provide the top-line results to the Company during the first half of November 2012. VACSP is the Company’s collaborator responsible for the management and statistical analyses of the data being collected from the trial.

Patrick J. McEnany, Catalyst's Chairman and Chief Executive Officer, stated: "Previously, VACSP had advised us that they would be able to provide top-line results from our trial around the end of September 2012. However, they have now indicated that it is taking longer than they had originally anticipated to obtain, verify and lock the drug use data from the trial, therefore delaying the timing of the delivery of the top-line results to us. We still expect to report these results significantly earlier than we had originally anticipated."

About the CPP-109 Phase II(b) Clinical Trial

The 24-week CPP-109 Phase II(b) clinical trial is randomized, double-blind and placebo- controlled in 207 patients recruited at 13 sites in the United States. It is designed to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 who abstain from cocaine use in the last two weeks of the trial’s treatment phase (weeks 8 and 9) will be higher than patients treated with placebo. Other outcomes include: i) reduction in cocaine use days; ii) increase in clean urines collected; and iii) improvements in other measures of subject well-being and cocaine craving.

About CPP-109 and Fast Track Status

CPP-109 is a GABA analog that is Catalyst’s designation for vigabatrin. Catalyst licensed CPP- 109 from Brookhaven National Laboratory for the treatment of cocaine and other addictions, and has been granted “Fast Track” status by the U.S. Food and Drug Administration (FDA) for cocaine addiction. Under the Federal Food, Drug, and Cosmetic Act, the FDA is directed to facilitate the development and expedite review of drugs and biologics intended to treat serious or life-threatening conditions, and that demonstrate the potential to address unmet medical needs. Fast Track designation emphasizes communication between Catalyst and the FDA, and provides Catalyst benefits that may help to expedite the approval process. For example, Fast Track designation affords Catalyst the potential to submit a New Drug Application (NDA) for CPP-109 on a rolling or modular basis, allowing the FDA to review sections of the NDA in advance of receiving a full submission. The designation also means that Catalyst may have increased communications with the FDA regarding the design of its clinical studies, which may expedite the development and review of Catalyst’s application for the approval of CPP-109 for cocaine addiction and may provide greater certainty overall in the regulatory pathway.

About Cocaine Addiction

According to the most recent Substance Abuse and Mental Health Services Administration (SAMHSA) survey, an estimated 1.4 million people, or 0.5% of the population aged 12 or over, had used cocaine in the month preceding the survey. Additionally, in 2011, approximately 670,000 people aged 12 or over had used cocaine for the first time within the preceding 12 months, an average of approximately 1,800 new users per day. In addition, approximately 511,000 patients received their most recent treatment for cocaine abuse in 2011.

Cocaine addiction is not only a U.S. health problem. In 2009, according to the United Nations Office on Drugs and Crime, there were 4.3 million – 4.7 million users of cocaine between the ages of 15 and 64 across Europe who had used it within the past year. Catalyst believes that the direct and indirect costs of cocaine use are indicative of a global public health problem, representing a significant unmet medical need for which no adequate pharmaceutical therapies exist.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system, including addiction and epilepsy. Catalyst has two products in development, CPP-109 and CPP-115. It is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109, for the treatment of cocaine addiction. Both CPP-109 and CPP-115 have been granted “Fast Track” status by the FDA for the treatment of cocaine addiction. Catalyst is also planning to evaluate CPP-109 for the treatment of other addictions. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. For more information about Catalyst, go to www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether CPP-109 will be safe and effective for the treatment of addiction, the anticipated timing of the Company’s receipt of the top-line results of its Phase II(b) trial, whether the CPP-109 Phase Page 3 II(b) clinical trial will be successful, whether any of the above-described benefits from having received Fast Track status from the FDA for CPP-109 will be realized by the Company, whether CPP-109 will ever be approved for commercialization, and those other factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company’s website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.